DiaMedica Therapeutics Inc (DMAC) reports a robust cash position and significant clinical advancements, despite facing enrollment challenges in its ReMEDy2 trial. MINNEAPOLIS, March 17, 2025 ...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced the peer-reviewed ...

An update from Diamedica Therapeutics ( (DMAC)) is now available. On February 20, 2025, DiaMedica Therapeutics appointed Daniel J. O’Connor to its Board of Directors, recognizing his extensive ...

H.C. Wainwright analyst Matthew Caufield raised the firm’s price target on DiaMedica Therapeutics (DMAC) to $10 from $7 and keeps a Buy rating on the shares. The firm believes the greatest near ...

Hello everyone and welcome to our full year 2024. Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics full year 2024 conference call. An audio recording of the webcast ...

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases ...

“We made significant progress in 2024, advancing our AIS program and expanding into preeclampsia,” said Rick Pauls, President and CEO of DiaMedica. “Both of these populations are critically ...

DIAMEDICA THERAPEUTICS ($DMAC) posted quarterly earnings results on Monday, March 17th. The company reported earnings of -$0.18 per share, missing estimates of -$0.18 ...

Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Full Year 2024 Conference Call. An audio recording of the webcast will be available shortly after the call today on ...